secretagogue


Also found in: Medical, Wikipedia.

se·cre·ta·gogue

 (sĭ-krē′tə-gôg′, -gŏg′)
n.
A hormone or another agent that causes or stimulates secretion.

secretagogue

(sɪˈkriːtəɡɒɡ)
n
(Medicine) med a substance that stimulates secretion
seˌcretaˈgogic adj
Translations

se·cre·ta·gogue

, secretogogue
n. secretogogo, agente que estimula la secreción glandular.
References in periodicals archive ?
The use of the lipid--lowering drug gemfibrozil and the insulin secretagogue repaglinide puts people with type 2 diabetes at an increased risk of hypoglycemia.
On December 20, 2017, the US Food and Drug Administration granted marketing approval for Macrilen, an oral growth hormone secretagogue receptor agonist, to be used in the diagnosis of patients with adult growth hormone deficiency.
Food and Drug Administration (FDA) granted marketing approval for MACRILEN, an oral growth hormone secretagogue (GHS) receptor agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD), which affects approximately 60,000 adults in the U.
The company's cardiorenal portfolio includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis, and RDX013, a potassium secretagogue program.
Ghrelin, the endogenous ligand for the growth hormone secretagogue receptor, has been identified in the pancreas of many vertebrates.
The growth hormone production in response to growth hormone secretagogue is suppressed by growth hormone releasing hormone antagonist11.
There are some secretagogue agents currently under investigation by pharmaceutical companies.
Global Markets Direct's, 'Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016', provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted pipeline therapeutics.
Ghrelin is a gut/brain peptide comprising 28 amino acids and is originally identified as the endogenous ligand of the growth hormone secretagogue receptor (GHSR) (1, 2).
If the patient is currently taking an insulin secretagogue or insulin when an SGLT2 is added, consider lowering the dose of the insulin secretagogue or insulin to avoid hypoglycemia.
Ghrelin, a 28-amino acid polypeptide, was initially isolated from the human and rat stomach as an endogenous ligand of growth hormone secretagogue receptor type 1a (GHS-R1a) [7].
Full browser ?